



April 1, 2019

PRODUCT SUPPLY UPDATE – ETOPOSIDE INJECTION

^{Pr}ETOPOSIDE Injection, 20 mg/mL, DIN 02080036
^{Pr}Toposar® (etoposide injection), 20 mg/mL (US Labelled)

Dear Healthcare Provider,

Based on current demand and distribution patterns for the entire Canadian market, Teva projects that our combined supplies of Canadian Etoposide and US Toposar will last as follows:

Table 1: Current and expected re-supplies of all Etoposide Vials

Size	Current Months of Supply	Inbound Months of Supply	Total Months of Supply
5 mL	3	7	10
10 mL	3	8	11
25 mL	2	9	11
50 mL	13	0	13

- At this time, we are expecting re-supplies (inbound) of Canadian Etoposide for the 5mL vials in June 2019 and for the 10mL and 25mL vials in July 2019.
- Timelines and quantities are subject to change.
- For the foreseeable future, we are not able to obtain additional quantities of the US labelled Toposar product.
- We continue to work with our global supply chain for recurring replenishment with the aim of improving longer-term coverage.

The supply situation has not fully stabilized and it is critical that the ordering process communicated on February 15, 2019 be followed to ensure ongoing and fair access to product for patients.

Thank you for your understanding and continued support.

Hospital Division
Teva Canada Limited